|
| |
| KLSE: INIX (0094) | INIX TECHNOLOGIES HOLDINGS BHD | ACE : Technology |
| Last Price | Today's Change | Day's Range | Trading Volume |
| 0.315 |  -0.015 (4.55%) | 0.31 - 0.33 | 22,621,700 |
| Trade this stock and win a FREE I3investor T-shirt after 5 trades. Find out more. |
Financials
Market Cap: 147 Million
| Latest Audited Result: 31-Jan-2020
| Latest Quarter: 31-Oct-2020 [#3]
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Annual (Unaudited) ( EPS: -0.59, P/E: -53.68 )
| T4Q Result ( EPS: 0.46, P/E: 69.04 )
| Annualized Result ( EPS: -0.28, P/E: -113.18 )
|
Business Performance
Business Performance (By Quarter)
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Positive Profit Years | 2 / 4 | 50.00% | 3 / 8 | 37.50% |
| Continuous Quarters Of Positive Profit | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 2.58% | -1.83% | ||
| Average Net Profit Margin | -4.22% | -51.97% | ||
Business Performance (By Year)
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Years Of Revenue Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Positive Profit Years | 0 / 5 | 0.00% | 2 / 10 | 20.00% |
| Continuous Years Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Profit Growth | 3 / 5 | 60.00% | 3 / 10 | 30.00% |
| Continuous Years Of Adjusted EPS Growth | 3 / 5 | 60.00% | 3 / 10 | 30.00% |
| Total Dividend Years | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | -99.73% | -52.93% | ||
| Average Net Profit Margin | -134.11% | -82.13% | ||
Key Result
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 3,638 | 2,694 | 8,049 | 6,122 | 7,490 |
| NP to SH | 2,129 | -1,298 | -2,738 | -5,468 | -9,750 |
| Dividend | 0 | - | - | - | - |
| Adjusted EPS | 0.46 | -0.28 | -0.59 | -1.17 | -2.09 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | - | - |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
Growth (By Quarter)
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 21.14% | -34.08% | -68.58% | -16.22% | -29.51% |
| NP to Owner | -475.46% | -581.51% | 83.25% | -252.37% | -138.18% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adj. EPS | -475.46% | -581.51% | 83.25% | -252.37% | -138.18% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
Growth (By Year)
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -54.80% | -51.43% | -40.58% | -66.52% | -64.03% | -55.98% | -14.81% | 7.45% | 31.47% |
| NP to Owner | 177.76% | 121.83% | 138.93% | 52.57% | 86.68% | 76.25% | 82.14% | 71.92% | 49.93% |
| Dividend | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
| Adj. EPS | 177.76% | 121.83% | 138.93% | 52.57% | 86.68% | 76.25% | 82.14% | 71.92% | 49.93% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
 Manggalee https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123537 23/01/2021 1:06 PM ruby20 goreng stock. avoid. wanna buy glove shares buy first tier. wanna buy glove wannabe buy iconic 23/01/2021 1:15 PM STEADYBOMBIBI85 No official agreement or mou to distribute the vaccines for general public. Inix is only distributing the vaccines for clinical trial only. Part of their CSR initiative. 23/01/2021 3:51 PM Dankot Glove manufacturing is on or not...now oso want to distribute the vaccine is real or not.... 23/01/2021 4:48 PM  MadCow75 sorry.. what i understand only helping to source china vaccine... so everyone had own understanding... just pls read careful the notice... 23/01/2021 4:49 PM YuHainTeck Be patience. Will fly high once get approval from NPRA. Query from Bursa already answered. 23/01/2021 9:26 PM shadowz Glove production line started, going to increase every months, this counters is no more pure speculative but with strong earning prospects. And being a goreng stock is actually a surplus point to enter, better than those sleeping counter right...who knows next day it hits limit up again ler hahaha... 23/01/2021 11:01 PM STEADYBOMBIBI85 Its stated clearly in the first announcement if you bother to read until the end 24/01/2021 12:39 AM Wanamakemoney Slowly but surely. For trial 1st then distribute la.nobody wanting to do a donkey job. 24/01/2021 7:25 PM MadCow75 sorry.. im not negative person... i think bombibi still not so rite.. coz is write there help to source.. then mention few china vaccine... but china got so many lab research for covid vaccine... i dun think to help bring in for trial... is help to source only... 24/01/2021 10:09 PM dragon_loong Please read the whole announcement carefully until the end. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123537 Reference is made to the Company’s announcement made on 13 January 2021 and 20 January 2021. For clarification, the Board of Directors of INIX wishes to inform that Inix Network Sdn Bhd was appointed as distributors for the Covid-19 vaccine by Sinovac Biotech Co Ltd, Cansino Biologics Inc and Sinopharm China National Biotech Group Co Ltd on 28 October 2020. This announcement is dated 22 January 2021. 24/01/2021 10:58 PM STEADYBOMBIBI85 @dragon_loong Distribution here refers to distribution of vaccine for clinical trial participants, not distribution of vaccine for general public use. Inix will sponsor the vaccines for use in the clinical trial as part of their CORPORATE SOCIAL RESPONSIBILITY (CSR) INITIATIVE. Read until the end, especially the last paragrah of the 1st announcement. The hint is there. “ As and when iNix has received the approval from MoH, iNix would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as INIX’s CSR initiative. This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers.” The “approval” here refers to the approval to import the vaccine for purpose of clinical trial only and not approval for general public use in Malaysia. Otherwise why do you still need to conduct clinical trials when the approval of the vaccine by MOH is for general public use? Inix is playing around with words here to confuse and mislead the shareholders. Besides, there is no MOU or official distributor agreement between Sinovac, Cansino and Sinopharm with Inix. Otherwise, it would have been announced in Bursa Malaysia. https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=110697&name=EA_GA_ATTACHMENTS 25/01/2021 1:45 AM zalmiez82 Steadybombibi85 that way i said to you more matured and profesional. Sell vaccine is not like sell goreng pisang. It must goes step by step. 25/01/2021 7:22 AM Valueinvestor mentioned many times, this counter cannot greedy........ must earn that few cent only. the operator TCH not ambitious and focus on small money earn! 25/01/2021 11:34 AM STEADYBOMBIBI85 https://www.theedgemarkets.com/article/bioalpha-join-vaccine-distribution-bandwagon 25/01/2021 4:50 PM STEADYBOMBIBI85 The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha International Sdn. Bhd. (“BISB”), a wholly-owned subsidiary of Bioalpha has on 25 January 2021 entered into a Procurement and Distribution Agreement (“Agreement”) with Shanghai Bukun Trading Co., Ltd (“SBTC”), a wholly-owned subsidiary of Sinopharm (Hainan) Health Industry Co., Ltd (“Sinopharm Hainan”) for the procurement and distribution of vaccines in Malaysia, including but not limited to the Covid-19 vaccine developed by Sinovac Biotech Co., Ltd. (“Sinovac Biotech”), subject to relevant authorities’ approvals which include the National Pharmaceutical Regulatory Agency (“NPRA”). This arrangement has also been endorsed by Sinovac Biotech with regards to the Covid-19 vaccine. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123824 25/01/2021 4:51 PM Sneakpeek main activity is tech.. Change chairman thrice in a year Durian season MOU with durian supplier Then glove season MOU with glove manufacturer Then vaccine season MOU with all three China supplier in one go. hahahahahahah...open your eyes laa the sign so obvious. 25/01/2021 9:59 PM Valueinvestor when dive lower then buy more.. earn 20% not difficult from this counter. die hard fans know well...don keep dream will over 40 cent... 26/01/2021 3:37 PM dec_12 Look like is the time to buy in on next week. Show that is going to 25c soon... 26/01/2021 6:29 PM shadowz China & Russia vaccines done deal with Pharma & dpharma liao today , so confirm no chance for inix 26/01/2021 11:39 PM shadowz https://www.theedgemarkets.com/article/duopharma-signs-deal-putrajaya-supply-russian-covid19-vaccine 26/01/2021 11:40 PM shadowz https://focusmalaysia.my/markets/pharmaniaga-puts-faith-in-chinese-coronavac-vaccine-supplies-12m-doses-to-moh/ 26/01/2021 11:41 PM  |
|
